Literature DB >> 33505943

Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications.

Ana-Maria Singeap1,2, Carol Stanciu2, Laura Huiban1,2, Cristina Maria Muzica1,2, Tudor Cuciureanu1,2, Irina Girleanu1,2, Stefan Chiriac1,2, Sebastian Zenovia1,2, Robert Nastasa1,2, Catalin Sfarti1,2, Camelia Cojocariu1,2, Anca Trifan1,2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has a rising prevalence worldwide. Its potential for evolution towards liver cirrhosis and hepatocellular carcinoma, as well as associations with extrahepatic manifestations, represents a double burden for patients and physicians alike. Recently, there has been increasing evidence of the association between NAFLD and a number of endocrinopathies, such as hypothyroidism, polycystic ovarian syndrome (PCOS), hypopituitarism, growth hormone deficiency (GHD), hypogonadism, and hypercortisolism. Definite correlations are supported by clear evidence so far, but further studies are needed in order to completely clarify the pathogenic mechanisms and, especially, to identify therapeutic implications. In this review, we present the main relationships between NAFLD and endocrinopathies, emphasizing the reciprocal causality, evolutive interconnections, and current clinical scenarios of presentations of which the clinicians should be aware.
Copyright © 2021 Ana-Maria Singeap et al.

Entities:  

Year:  2021        PMID: 33505943      PMCID: PMC7814954          DOI: 10.1155/2021/6678142

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  80 in total

Review 1.  Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.

Authors:  Themistoklis Tzotzas; Spyridon N Karras; Niki Katsiki
Journal:  Curr Vasc Pharmacol       Date:  2017       Impact factor: 2.719

2.  Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease.

Authors:  Tatsuki Ichikawa; Kazuhiko Nakao; Keisuke Hamasaki; Ryuji Furukawa; Shotarou Tsuruta; Yasuo Ueda; Naota Taura; Hidetaka Shibata; Masumi Fujimoto; Kan Toriyama; Katsumi Eguchi
Journal:  Hepatol Int       Date:  2007-06-01       Impact factor: 6.047

3.  Resolution of non-alcoholic steatohepatitis after growth hormone replacement in a pediatric liver transplant patient with panhypopituitarism.

Authors:  Thomas Gilliland; Sylvie Dufour; Gerald I Shulman; Kitt Falk Petersen; Sukru H Emre
Journal:  Pediatr Transplant       Date:  2016-10-20

4.  Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction.

Authors:  Leon A Adams; Ariel Feldstein; Keith D Lindor; Paul Angulo
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

Review 5.  Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.

Authors:  Mehmet Sayiner; Aaron Koenig; Linda Henry; Zobair M Younossi
Journal:  Clin Liver Dis       Date:  2015-12-14       Impact factor: 6.126

6.  Insulin resistance in nonobese patients with polycystic ovarian disease.

Authors:  R J Chang; R M Nakamura; H L Judd; S A Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

Review 7.  Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.

Authors:  Ahad Eshraghian; Alireza Hamidian Jahromi
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

8.  Premature mortality due to cardiovascular disease in hypopituitarism.

Authors:  T Rosén; B A Bengtsson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

Review 9.  Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.

Authors:  Nicholas Michael Morton
Journal:  Mol Cell Endocrinol       Date:  2009-10-03       Impact factor: 4.102

10.  Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients.

Authors:  Lu Liu; Yong Yu; Meng Zhao; Dongmei Zheng; Xu Zhang; Qingbo Guan; Chao Xu; Ling Gao; Jiajun Zhao; Haiqing Zhang
Journal:  Int J Endocrinol       Date:  2017-04-04       Impact factor: 3.257

View more
  6 in total

1.  Recent insights into the pathogeneses and therapeutic targets of liver diseases: Summary of the 4th Chinese American Liver Society/Society of Chinese Bioscientists in America Hepatology Division Symposium in 2021.

Authors:  Wen-Xing Ding; Hua Wang; Yuxia Zhang
Journal:  Liver Res       Date:  2022-01-29

2.  Growth hormone ameliorates hepatopulmonary syndrome and nonalcoholic steatohepatitis secondary to hypopituitarism in a child: A case report.

Authors:  Xiao-Yuan Zhang; Ke Yuan; Yan-Lan Fang; Chun-Lin Wang
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

3.  Evaluation of thyroid function and thyroid autoimmune disease in patients with non-alcoholic fatty liver disease.

Authors:  Rania Naguib; Amel Fayed; Eman Z Elkemary; Hend Naguib
Journal:  Clin Exp Hepatol       Date:  2021-12-06

Review 4.  Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review.

Authors:  Madalena Von-Hafe; Marta Borges-Canha; Catarina Vale; Ana Rita Leite; João Sérgio Neves; Davide Carvalho; Adelino Leite-Moreira
Journal:  Metabolites       Date:  2022-03-29

Review 5.  Liver Abnormalities in Turner Syndrome: The Importance of Estrogen Replacement.

Authors:  Istvan Fedor; Eva Zold; Zsolt Barta
Journal:  J Endocr Soc       Date:  2022-08-11

Review 6.  Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS).

Authors:  Svetlana Spremović Rađenović; Miljan Pupovac; Mladen Andjić; Jovan Bila; Svetlana Srećković; Aleksandra Gudović; Biljana Dragaš; Nebojša Radunović
Journal:  Biomedicines       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.